Skip to main content

MicroMarvet - Fulcrum Therapeutics - Confusing Projections And Recommendation

Revenue is estimated to be down 63.40% this year and down another 19.80% next year. Earnings are projected to increase 32.80% this year but be down 9.80% next year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.